The ICR-CTSU manages a number of trials in different disease sites. Use the filter below to view trials for each cancer type:
Randomised phase II study of radiotherapy with and without synchronous chemotherapy in muscle invasive bladder cancer.
Randomised phase III placebo controlled trial evaluating the addition of celecoxib to standard treatment of transitional cell carcinoma of the bladder.
Phase II randomised feasibility study of chemoresection and surgical management in low risk non muscle invasive bladder cancer.
A multicentre, randomised phase II study of hypofractionated bladder radiotherapy with or without image guided adaptive planning.
Photo-dynamic versus white light-guided treatment of non-muscle invasive bladder cancer: randomised phase III trial of clinical and cost-effectiveness.
Phase III randomised trial of peri-operative chemotherapy versus surveillance in upper tract urothelial cancer.
Randomised trial of selective bladder preservation against radical excision (cystectomy) in muscle invasive T2/T3 transitional cell carcinoma of the bladder – feasibility study.
The division carries out or coordinates high-quality trials and translational research at both an early phase – typically to test new targeted drugs – and a later stage.